TY - JOUR
T1 - Hemolytic anemia after switching from infliximab originator to biosimilar CT-P13 in a patient with inflammatory bowel disease: A case report
AU - Strik, Anne S.
AU - D’Haens, Geert R.
AU - Löwenberg, Mark
PY - 2019
Y1 - 2019
N2 - Available data on switching from originator infliximab to CT-P13 in patients with inflammatory bowel disease are reassuring regarding safety and efficacy outcomes. However, monitoring of such patients, especially in the early phase after switching, is important given the possibility that rare side effects might occur, as illustrated here.
AB - Available data on switching from originator infliximab to CT-P13 in patients with inflammatory bowel disease are reassuring regarding safety and efficacy outcomes. However, monitoring of such patients, especially in the early phase after switching, is important given the possibility that rare side effects might occur, as illustrated here.
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85074011348&origin=inward
U2 - https://doi.org/10.1002/ccr3.2394
DO - https://doi.org/10.1002/ccr3.2394
M3 - Article
C2 - 31788249
SN - 2050-0904
JO - Clinical Case Reports
JF - Clinical Case Reports
ER -